No products in the basket.
Alector, Inc. a clinical-stage biotechnology company pioneering immuno-neurology, has announced the conclusion of a debt financing agreement with Hercules Capital, Inc. for up to US$50m. The agreement stipulates a US10m at closing (Alector drew it), an additional US$15m till June...
#Alector#debt finance#Hercules Capital